281 related articles for article (PubMed ID: 26060285)
1. Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy.
Siberry GK; Jacobson DL; Kalkwarf HJ; Wu JW; DiMeglio LA; Yogev R; Knapp KM; Wheeler JJ; Butler L; Hazra R; Miller TL; Seage GR; Van Dyke RB; Barr E; Davtyan M; Mofenson LM; Rich KC;
Clin Infect Dis; 2015 Sep; 61(6):996-1003. PubMed ID: 26060285
[TBL] [Abstract][Full Text] [Related]
2. Meconium Tenofovir Concentrations and Growth and Bone Outcomes in Prenatally Tenofovir Exposed HIV-Uninfected Children.
Himes SK; Wu JW; Jacobson DL; Tassiopoulos K; Hazra R; Kacanek D; Van Dyke RB; Rich KC; Siberry GK; Huestis MA;
Pediatr Infect Dis J; 2015 Aug; 34(8):851-7. PubMed ID: 25961889
[TBL] [Abstract][Full Text] [Related]
3. Tenofovir Disoproxil Fumarate Use during Pregnancy and Infant Bone Health: the Tenofovir in Pregnancy Pilot Study.
Kourtis AP; Wiener J; Wang L; Fan B; Shepherd JA; Chen L; Liu W; Shepard C; Wang L; Wang A; Bulterys M
Pediatr Infect Dis J; 2018 Nov; 37(11):e264-e268. PubMed ID: 30067600
[TBL] [Abstract][Full Text] [Related]
4. Bone Age and Mineral Density Assessments Using Plain Roentgenograms in Tenofovir-exposed Infants in Malawi and Brazil Enrolled in HIV Prevention Trials Network 057.
Osorio LE; Boechat MI; Mirochnick M; Kumwenda N; Kreitchmann R; Emel L; Pinto J; Joao E; Santos B; Swenson M; George K; Sato P; Mofenson L; Nielsen-Saines K;
Pediatr Infect Dis J; 2017 Feb; 36(2):184-188. PubMed ID: 27798550
[TBL] [Abstract][Full Text] [Related]
5. Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy.
Ransom CE; Huo Y; Patel K; Scott GB; Watts HD; Williams P; Siberry GK; Livingston EG;
J Acquir Immune Defic Syndr; 2013 Dec; 64(4):374-81. PubMed ID: 24169122
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial.
Lockman S; Brummel SS; Ziemba L; Stranix-Chibanda L; McCarthy K; Coletti A; Jean-Philippe P; Johnston B; Krotje C; Fairlie L; Hoffman RM; Sax PE; Moyo S; Chakhtoura N; Stringer JS; Masheto G; Korutaro V; Cassim H; Mmbaga BT; João E; Hanley S; Purdue L; Holmes LB; Momper JD; Shapiro RL; Thoofer NK; Rooney JF; Frenkel LM; Amico KR; Chinula L; Currier J;
Lancet; 2021 Apr; 397(10281):1276-1292. PubMed ID: 33812487
[TBL] [Abstract][Full Text] [Related]
7. Maternal Tenofovir Disoproxil Fumarate Use in Pregnancy and Growth Outcomes among HIV-Exposed Uninfected Infants in Kenya.
Pintye J; Langat A; Singa B; Kinuthia J; Odeny B; Katana A; Nganga L; John-Stewart G; McGrath CJ
Infect Dis Obstet Gynecol; 2015; 2015():276851. PubMed ID: 26823647
[TBL] [Abstract][Full Text] [Related]
8. Safety of tenofovir during pregnancy: early growth outcomes and hematologic side effects in HIV-exposed uninfected infants.
Seidel V; Weizsäcker K; Henrich W; Rancourt RC; Bührer C; Krüger R; Feiterna-Sperling C
Eur J Pediatr; 2020 Jan; 179(1):99-109. PubMed ID: 31659467
[TBL] [Abstract][Full Text] [Related]
9. Safety of Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis.
Nachega JB; Uthman OA; Mofenson LM; Anderson JR; Kanters S; Renaud F; Ford N; Essajee S; Doherty MC; Mills EJ
J Acquir Immune Defic Syndr; 2017 Sep; 76(1):1-12. PubMed ID: 28291053
[TBL] [Abstract][Full Text] [Related]
10. Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.
Gibb DM; Kizito H; Russell EC; Chidziva E; Zalwango E; Nalumenya R; Spyer M; Tumukunde D; Nathoo K; Munderi P; Kyomugisha H; Hakim J; Grosskurth H; Gilks CF; Walker AS; Musoke P;
PLoS Med; 2012; 9(5):e1001217. PubMed ID: 22615543
[TBL] [Abstract][Full Text] [Related]
11. Impact of postpartum tenofovir-based antiretroviral therapy on bone mineral density in breastfeeding women with HIV enrolled in a randomized clinical trial.
Stranix-Chibanda L; Tierney C; Sebikari D; Aizire J; Dadabhai S; Zanga A; Mukwasi-Kahari C; Vhembo T; Violari A; Theron G; Moodley D; George K; Fan B; Sommer MJ; Browning R; Mofenson LM; Shepherd J; Nelson B; Fowler MG; Siberry GK;
PLoS One; 2021; 16(2):e0246272. PubMed ID: 33544759
[TBL] [Abstract][Full Text] [Related]
12. Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants.
Siberry GK; Williams PL; Mendez H; Seage GR; Jacobson DL; Hazra R; Rich KC; Griner R; Tassiopoulos K; Kacanek D; Mofenson LM; Miller T; DiMeglio LA; Watts DH;
AIDS; 2012 Jun; 26(9):1151-9. PubMed ID: 22382151
[TBL] [Abstract][Full Text] [Related]
13. In Utero Tenofovir Exposure Is not Associated With Fetal Long Bone Growth.
Jao J; Abrams EJ; Phillips T; Petro G; Zerbe A; Myer L
Clin Infect Dis; 2016 Jun; 62(12):1604-1609. PubMed ID: 27009251
[TBL] [Abstract][Full Text] [Related]
14. Growth indices in breastfed infants pre and postnatally exposed to tenofovir compared with tenofovir-unexposed infants.
Liotta G; Floridia M; Andreotti M; Jere H; Sagno JB; Marazzi MC; Buonomo E; Scarcella P; Mancinelli S; Vella S; Giuliano M; Palombi L
AIDS; 2016 Jan; 30(3):525-7. PubMed ID: 26765942
[TBL] [Abstract][Full Text] [Related]
15. Lower birth weight-for-age and length-for-age z-scores in infants with in-utero HIV and ART exposure: a prospective study in Cape Town, South Africa.
Nyemba DC; Kalk E; Madlala HP; Malaba TR; Slogrove AL; Davies MA; Boulle A; Myer L; Powis KM
BMC Pregnancy Childbirth; 2021 May; 21(1):354. PubMed ID: 33947351
[TBL] [Abstract][Full Text] [Related]
16. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Mayer KH; Molina JM; Thompson MA; Anderson PL; Mounzer KC; De Wet JJ; DeJesus E; Jessen H; Grant RM; Ruane PJ; Wong P; Ebrahimi R; Zhong L; Mathias A; Callebaut C; Collins SE; Das M; McCallister S; Brainard DM; Brinson C; Clarke A; Coll P; Post FA; Hare CB
Lancet; 2020 Jul; 396(10246):239-254. PubMed ID: 32711800
[TBL] [Abstract][Full Text] [Related]
17. Birth Outcomes for Pregnant Women with HIV Using Tenofovir-Emtricitabine.
Rough K; Seage GR; Williams PL; Hernandez-Diaz S; Huo Y; Chadwick EG; Currier JS; Hoffman RM; Barr E; Shapiro DE; Patel K;
N Engl J Med; 2018 Apr; 378(17):1593-1603. PubMed ID: 29694825
[TBL] [Abstract][Full Text] [Related]
18. Long-term growth and bone development in children of HBV-infected mothers with and without fetal exposure to tenofovir disoproxil fumarate.
Wen WH; Chen HL; Shih TT; Wu JF; Ni YH; Lee CN; Zhao LL; Lai MW; Mu SC; Tung YC; Hsu HY; Chang MH;
J Hepatol; 2020 Jun; 72(6):1082-1087. PubMed ID: 32044401
[TBL] [Abstract][Full Text] [Related]
19. Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding.
Mofenson LM; Baggaley RC; Mameletzis I
AIDS; 2017 Jan; 31(2):213-232. PubMed ID: 27831952
[TBL] [Abstract][Full Text] [Related]
20. Tenofovir exposure in utero and linear growth in HIV-exposed, uninfected infants.
M le Roux S; Jao J; Brittain K; Phillips TK; Olatunbosun S; Ronan A; Zerbe A; Abrams EJ; Myer L
AIDS; 2017 Jan; 31(1):97-104. PubMed ID: 27898591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
